ArticleAmerican journal of obstetrics and gynecology2017
Risk of metachronous ovarian cancer after ovarian conservation in young women with stage I cervical cancer.
Article in American journal of obstetrics and gynecology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Skin Metastasis from Cervical Adenocarcinoma with Intrapulmonary Metastasis and Metachronous Ovarian Cancer Responding to Chemotherapy: A Case Report and Review.Cancer management and research · 2025Article
- Influence of ovarian-sparing surgery and ovariectomy on prognosis in early cervical adenocarcinoma: a systematic review and meta-analysis.Gland surgery · 2022Article
- Time Intervals between Double Primary Breast and Ovarian Cancers and Survival Outcomes of Patients with Both Cancers: A SEER Database Analysis.BioMed research international · 2022Article
- EML4-NTRK3 Fusion Cervical Sarcoma: A Case Report and Literature Review.Frontiers in medicine · 2022Article
- Should adjuvant chemotherapy be formally studied among patients found to have pelvic lymph node metastases following radical hysterectomy with lymphadenectomy for early-stage cervical cancer?Journal of gynecologic oncology · 2021Article
- Evolving population-based statistics for rare epithelial ovarian cancers.Gynecologic oncology · 2020Observational
- Safety and Prognostic Impacts of Ovarian Preservation during Radical Hysterectomy for Early-Stage Adenocarcinoma and Adenosquamous Cervical Cancer.BioMed research international · 2020Article
- Tumor-specific outcome of metachronous uterine malignancy after pelvic irradiation for cervical cancer.Gynecologic oncology · 2018Article
- Association of tumor differentiation grade and survival of women with squamous cell carcinoma of the uterine cervix.Journal of gynecologic oncology · 2018Observational
- Incidences and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis.Gynecologic oncology · 2018Article
- Adequate pelvic lymphadenectomy and survival of women with early-stage epithelial ovarian cancer.Journal of gynecologic oncology · 2018Observational
- Article
- Identifying a candidate population for ovarian conservation in young women with clinical stage IB-IIB cervical cancer.International journal of cancer · 2018Article
- Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer.Gynecologic oncology · 2017Article
Corrections and comments
- Commented on by
- Commented on byReply.2018
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundWhile there is an increasing trend of ovarian conservation at the time of surgical treatment for young women with stage I cervical cancer, the risk for subsequent ovarian cancer after ovarian conservation has not been well studied.
objectiveWe sought to examine the incidence of and risk factors for metachronous ovarian cancer among young women with stage I cervical cancer who had ovarian conservation at the time of hysterectomy. STUDY
designThe Surveillance, Epidemiology, and End Results Program was used to identify women aged <50 years who underwent hysterectomy with ovarian conservation for stage I cervical cancer from 1983 through 2013 (n = 4365). Time-dependent analysis was performed for ovarian cancer risk after cervical cancer diagnosis.
resultsMean age at cervical cancer diagnosis was 37 years, and the majority of patients had stage IA disease (68.2%) and squamous histology (72.9%). Median follow-up time was 10.8 years, and there were 13 women who developed metachronous ovarian cancer. The 10- and 20-year cumulative incidences of metachronous ovarian cancer were 0.2% (95% confidence interval, 0.1-0.4) and 0.5% (95% confidence interval, 0.2-0.8), respectively. Mean age at the time of diagnosis of metachronous ovarian cancer was 47.5 years, and stage III-IV disease was seen in 55.6%. Age (≥45 vs <45 years, hazard ratio, 4.22; 95% confidence interval, 1.16-15.4; P = .018), ethnicity (non-white vs white, hazard ratio, 4.29; 95% confidence interval, 1.31-14.0; P = .009), cervical cancer histology (adenocarcinoma or adenosquamous vs squamous, hazard ratio, 3.50; 95% confidence interval, 1.17-10.5; P = .028), and adjuvant radiotherapy use (yes vs no, hazard ratio, 3.69; 95% confidence interval, 1.01-13.4; P = .034) were significantly associated with metachronous ovarian cancer risk. The presence of multiple risk factors was associated with a significantly increased risk of metachronous ovarian cancer compared to the no risk factor group: 1 risk factor (hazard ratio range, 2.96-8.43), 2 risk factors (hazard ratio range, 16.6-31.0), and 3-4 risk factors (hazard ratio range, 62.3-109), respectively.
conclusionMetachronous ovarian cancer risk after ovarian conservation for women with stage I cervical cancer is <1%. Older age, non-white ethnicity, adenocarcinoma or adenosquamous histology, and adjuvant radiotherapy may be associated with an increased metachronous ovarian cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.